Endovascular treatment of aortic pseudoaneurysm in Behçet disease  by Liu, Chang-Wei et al.
Endovascular treatment of aortic pseudoaneurysm
in Behçet disease
Chang-Wei Liu, MD,a Wei Ye, MD,a Bao Liu, MD,a Rong Zeng, MD,a Weiwei Wu, MD,a and
Michael D. Dake, MD,b Beijing, China; and Stanford, Calif
Objective: This study evaluated the feasibility, efficacy, and outcome of endovascular therapy combined with immuno-
suppressive therapy for aortic pseudoaneurysms in patients with Behçet disease.
Methods: Between April 2002 and April 2008, 12 pseudoaneurysms (9 involving the intrarenal abdominal aorta, 1 at the
suprarenal level, and 2 in the supraceliac aorta) in nine men and one woman with Behçet disease were evaluated at Peking
Union Medical Center (PUMC). Three bifurcated stent grafts and seven tubular stent grafts, including two fenestrated
stent grafts, were deployed. All 10 patients received immunosuppressive therapy after the implant procedure.
Results: All patients underwent successful endovascular therapy without major complications during the 30 days
immediately after the procedure. One patient with two aneurysms had treatment of only the larger infrarenal
symptomatic aneurysm, but the smaller suprarenal pseudoaneurysm was not addressed because of its proximity to
mesenteric branches. During a mean follow-up of 25.8 months (range, 6-50 months), nine aneurysms resolved
completely in eight patients. The only untreated aneurysm, which coexisted with a treated lesion, remained stable under
imaging observation. Three aneurysms recurred in two patients. At 6 months, one patient presented with a new aneurysm
at the femoral artery access site for stent graft introduction and another formed at the proximal margin of the stent graft.
Despite medical advice, he had stopped immunotherapy. He died from aneurysm rupture 8 months after stent
deployment. Another patient with recurrent aneurysmal disease at the distal margin of the primary stent was successfully
treated with an additional stent graft. These two were the only patients who did not adhere to taking immunosuppressant
medicine after discharge.
Conclusion: Endovascular stent graft placement combined with immunosuppressive treatment for aortic pseudoaneu-
rysms in Behçet disease is a feasible and effective management option. Long-term immunosuppressive therapy after
endovascular repair is important to limit pseudoaneurysm recurrence. ( J Vasc Surg 2009;50:1025-30.)Arterial involvement in Behçet disease (BD) is not
commonly seen, with several studies documenting preva-
lences of 2.2% to 18% of patients and aortic lesions in 1.5%
to 2.7%.1-4 Aortic involvement is one of the most severe
manifestations and is associated with a much higher mor-
tality than that observed in BD patients without aortic
disease.1-4 Open surgical repair is recommended in most
patients, but postoperative complications, such as graft
occlusions or anastomotic pseudoaneurysm formation, are
frequent.5-7
Initial reports suggest that endovascular stent grafting
may provide an alternative treatment option in these com-
plicated cases, although the encouraging results are limited
to only short-term follow-up.8-10 Nitecki et al11 reported
that endovascular treatment offers lower combined mortal-
ity and morbidity (especially in cases of anastomotic
pseudoaneurysms) than open surgery. In this article, we
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ment of aortic pseudoaneurysm in 10 patients with BD.
MATERIALS AND METHODS
Between April 2002 and April 2008, nine men and one
woman with BD underwent evaluation and endovascular
treatment of 12 aortic pseudoaneurysms. Their median age
was 35.5 years (range, 24-54 years). The diagnosis of BD
was confirmed using the criteria detailed by the Interna-
tional Study Group for Behçet’s Disease.12 This required
documentation of recurrent oral ulceration in association
with at least two of the following: characteristic ocular
lesions, characteristic skin lesions, genital ulceration, and
positive pathergy test.
Patient clinical data are summarized in Table I. The
pseudoaneurysms were diagnosed with computed tomog-
raphy angiography (CTA) or angiography. Nine patients
had 11 spontaneous, nontraumatic pseudoaneurysms. One
patient’s pseudoaneurysm was associated with penetration
of the aorta by legs of an inferior vena cava filter. The most
frequent symptoms were abdominal and back pain (8 of 10
patients). Two patients with chronic aortic lesions (patients
1 and 8) did not experience pain before undergoing the
endovascular procedure.
Immunosuppressive treatment. Three patients (pa-
tients 3, 5, and 6), who had symptomatic pseudoaneurysms
and imaging evidence of life-threatening aortic rupture,
received intravenous glucocorticoids (hydrocortisone, 200
mg/d), and cyclophosphamide (200 mg/d) was com-
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endovascular therapy. At the time of the procedure, their
erythrocyte sedimentation rates (ESR) were 33 to 62
mm/h (normal reference range, 8-15 mm/h), and C-
reactive protein (CRP) values were 40 to 56 mg/L
(normal, 0.1-0.5 mg/L).
Five symptomatic patients (patients 2, 4, 7, 9, and 10)
with nonruptured pseudoaneurysms were administered im-
munosuppressive treatment with oral prednisone (60
mg/d) combined with cyclophosphamide (200 mg/d) for
1 to 3 weeks until the ESR and CRP values were within the
normal range. Once their inflammatory markers normal-
ized, they underwent endovascular stent graft implanta-
tion. Patients 1 and 8 received oral immunosuppressive
treatment with prednisone (5 to 10 mg/d) for 1 year before
stent graft placement. At the time of the procedures, their
respective ESR and CRP values were 3 and 6 mm/h and
0.3 and 0.9 mg/L.
After the endograft procedure, intravenous hydrocor-
tisone (200 mg/d) combined with cyclophosphamide
(200 mg/d) was continued for at least 3 days. The eight
acute and subacute patients then began receiving oral pred-
nisone (60 mg/d) and cyclophosphamide (200 mg/qod).
This drug regimen was tapered intermittently, adjusted in
conjunction with the individual patient’s response and
guidelines provided by the consulting rheumatologists. All
patients were advised to maintain immunosuppressive ther-
apy for at least 2 years.
Endovascular stent grafting. Endovascular stent
grafts were deployed successfully in all patients. The time
from diagnosis to treatment was between 3 hours and 1
year. Three patients underwent stent graft implantation
within hours of the diagnosis, five between 1 and 3 weeks of
the diagnosis, and the two chronic asymptomatic patients
underwent the endograft procedure at 1 year after long-
Table I. Patient demographics, clinical features, details of
Patient Sex
Age
Y Aortic manifestation
1 M 26 2 pseudoaneurysms 1 ju
2 M 54 Pseudoaneurysm Jux
3 M 24 Ruptured pseudoaneurysm Bifu
4 M 35 Pseudoaneurysm Infr
5 M 53 Ruptured pseudoaneurysm Jux
6 M 46 Ruptured pseudoaneurysm Infr
7 M 27 Pseudoaneurysm Infr
8 M 36 Pseudoaneurysm Bifu
9 M 49 2 pseudoaneurysms 1 S
10 F 35 Pseudoaneurysm Sup
AMI, Acute myocardial infarction; CIA, common iliac artery; CRP, C-rea
F, female; ICA, internal carotid artery; M, male; PFA, profounder femoral a
aNormal ESR value 20 mm/h.
bNormal CRP reference range, 0 to 8.0 mg/L.term immunosuppressive drug therapy.The choice of the stent graft design was based on the
individual patient’s anatomy, especially the proximity of the
lesion(s) to aortic branch vessels. Three bifurcated stent
grafts were deployed for abdominal aortic aneurysms adja-
cent to the aortic bifurcation. Seven tubular stent grafts were
implanted to repair pseudoaneurysms with sufficient proximal
and distal aortic neck segments of healthy vessel appropriate
for anchoring the graft. In this group, two stent grafts were
deployed in the supraceliac aorta, and five stent grafts were
placed in the infrarenal aorta. Two fenestrated grafts were also
used. The devices did not have barbs, hooks, or other anchors
to provide supplemental fixation, and in three instances, a
terminal bare stent body was removed to limit the potential of
injury to a diseased aorta.
Of note, there were three special cases in our series.
One patient with two aneurysms was treated with a tubular
stent graft for the larger symptomatic infrarenal aneurysm;
however, another smaller suprarenal lesion was conserva-
tively managed because it was close to visceral branches.
Two patients with juxtarenal aneurysms were treated suc-
cessfully using fenestrated stent grafts. The graft fenestra-
tions included one with a scallop (Fig 1) and one with a
small window and scallop (Fig 2). These unique custom-
fabricated grafts were created with the use of Hercules-T
stent grafts, which combine a nitinol stent endoskeleton
with polytetrafluoroethylene graft material (MicroPort
Medical, Inc., Shanghai, China) and manual shearing to
fashion the openings. The locations of the fenestrations
were preoperatively planned with the use of multiplanar
CTA imaging and created by the surgeon during the oper-
ation to accommodate the target renal ostia.
RESULTS
Ten patients underwent stent graft placement for ab-
dominal aortic pseudoaneurysms. The signs and symptoms
t grafting, and follow-up data
Pseudoaneurysm details
Interval between
diagnosis and treatmentLocation
Max
diameter, mm
nal; 1 infrarenal 22 1 y
al 16 3 d
on 28 12 h
l 24 3 wk
ac artery 36 4 h
l 142 3 h
l 20 1 wk
on 26 1 y
enal; 1 infrarenal 24 2 wk
iac 18 2 wk
rotein; DVT, deep vein thrombosis; ESR, erythrocyte sedimentation rate;sten
xtare
taren
rcati
arena
taceli
arena
arena
rcati
uprar
racel
ctive p
rtery.that led to the diagnosis of BD included recurrent oral ulcer
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positive pathergy test (40%), and ocular lesion (20%). Ele-
vations of ESR and CRP values were observed in all but the
two chronic patients who had received immunosuppressant
therapy for 1 year. ESR and CRP values for the patients are
detailed in Table I.
Ten procedures were performed for the 10 patients. All
the stent graft deployments were successful, including three
bifurcated stent grafts, five tubular stent grafts, and two
tubular fenestration stent grafts. All the stent grafts were
introduced through surgical cutdown and femoral arteriot-
omy. All of the procedures were performed150 minutes,
with blood loss of 50 mL uniformly.
No endoleaks were identified on completion aortogra-
phy. No balloon dilation or molding of the stent graft after
deployment was performed. Primary closure of the femoral
artery without the use of a patch was used in all cases;
percutaneous access or closure of the femoral artery was not
used. Three urgent procedures were performed for life-
threatening ruptured pseudoaneurysms. There were no
groin wound infections, stent occlusions, or deaths 30
days after the procedure.
After hospital discharge, patient follow-up was 100%
for a mean of 25.8 months (range, 6-50 months). Recur-
rent pseudoaneurysms were documented in two patients.
Patient 3 discontinued immunotherapy after hospital dis-
charge, against medical recommendations and without
knowledge of his physicians. At 6 months after the proce-
dure, a new pseudoaneurysm at the femoral artery access
site and another pseudoaneurysm at the proximal edge of
the stent graft were diagnosed. He presented as an emer-
gency at another hospital 8 months after the initial proce-
dure and died of rupture of the aortic pseudoaneurysm. In
the other patient, a second stent graft was deployed 6
Table I. Continued.
Other vascular involvement
Inflammatory
markers
St
graft
ESR,
mm/ha
CRP,
mg/Lb
3 1.2 Tub
Left lower limb DVT 29 18 Tub
62 56 Bifu
History of AMI, left ICA aneurysm 21 24 Tub
45 55 Tub
1 more aneurysm on right CIA,
1 aneurysm on left PFA
33 40 Bifu
Right lower limb DVT 68 89 Tub
History of AMI, left lower limb DVT 6 2.5 Bifu
27 5.7 Tub
18 6.7 Tubmonths after the initial procedure to treat recurrence of theprimary aneurysm that occurred after he refused to main-
tain immunosuppressive therapy. In the patient who died,
values for CRP and ESR were not obtained at the time of
the recurrent aortic pseudoaneurysm rupture. For the other
patient with a pseudoaneurysm, ESR was 21 mm/h and
CRP was 5.3 mg/L. This patient underwent a successful
reintervention and was maintained on immunosuppressive
therapy for 1 year after the second procedure.
The overall survival rate is 90% in our series. The
complication-free survival rate is 80% (8 of 10). The patient
with the untreated suprarenal pseudoaneurysm continues
to undergo CT imaging surveillance without a change in
the aneurysm size, 6 months after hospital discharge.
DISCUSSION
BD is an autoimmune disorder that involves multiple
organs. The prevalence of BD has a marked geographic
variation. The United Kingdom has an estimated 2000 BD,
but the prevalence is much higher in Japan at 10 per
100,000 and in Turkey at 8 to 38 per 100,000 popula-
tion.13 The prevalence in China is unknown.
Aortic involvement occurs in approximately one-third
of BD patients with vascular disease,3 and it is more com-
mon in men. The initial presentation of the disease usually
occurs between age 20 and 30 years. Vasculitis is believed
to be the main pathophysiologic lesion underlying vascular
disease in BD. Venous thrombosis, arterial thrombosis, and
arterial aneurysm are the most common manifestation of
the inflammatory vascular component of BD. Arterial in-
volvement usually indicates a poor prognosis for patients
with BD and accounts for most of the deaths.1,4
Aortic pseudoaneurysm is the most lethal lesion in BD.
The incidence of rupture and death is uncertain, but these
lesions are generally considered high risk. Surgical treat-
n
Adjunctive alteration
of device
Aneurysm
recurrence
Follow-up
mon
Patient
status
Custom fenestration 44 Alive
47 Alive
6 mon 8 Died
Remove bare stent cuff 4 mon 16 Alive
18 Alive
Remove bare stent cuff 50 Alive
Remove bare stent cuff 36 Alive
25 Alive
Suprarenal aneurysm;
being observed with
follow-up imaging
6 Alive
8 Aliveent
desig
e
e
rcated
e
e
rcated
e
rcated
e
ement is deemed essential; however, aortic pseudoaneurysm
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ogy by vascular surgeons because of the technical operative
difficulties and frequent recurrence. Several articles detail
the complications of open surgical treatment for aortic
pseudoaneurysm.5,6,11,14-16 Aneurysm-related mortality
with surgery is 10% to 30%, and recurrent false aneurysm at
an anastomotic site develops in 10% to 50% of patients.
Graft occlusion or infection, as well as thromboembolic
events, are also not uncommon (Table II).
Endovascular treatment is a recent innovation that may
prove to be the treatment of choice in patients with major
Fig 1. Aortic pseudoaneurysm involving the infrarenal segment
in patient 1. A, Aortogram before stent placement displays an
irregular, multilobed lesion adjacent to the accessory left renal
artery. B, Completion aortogram after stent graft deployment
confirms exclusion with preserved perfusion of the left accessory
renal artery to the lower pole of the kidney.risk factors for open surgery. In 1998 Vasseur et al8 firstreported endovascular treatment of a BD patient with
aortoiliac false aneurysms using a bifurcated stent graft.
This showed that endovascular treatment could provide a
feasible, less invasive alternative to surgery for patients with
aortic pseudoaneurysm due to BD.
Since their initial description, other investigators have
reported experience with endoluminal treatment in an at-
tempt to eliminate the potential for aneurysm formation at
anastomotic sites or to treat a recurrent aneurysm at an
anastomotic site.11,17,18 To our knowledge, our series of
10 patients is the largest experience from a single center,
and the outcomes strengthen the case for endoluminal
treatment as an alternative to open surgical repair. Table II
Fig 2. Juxtarenal pseudoaneurysm in patient 2. A, Aortogram
shows eccentric, left-sided, saccular, pseudoaneurysm opposite the
right renal artery and immediately distal to the left renal artery.
B, Aortogram after fenestrated stent graft placement shows no
opacification of the aneurysm and normal visualization of the renal
arteries.details the experience reported in the medical literature
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for the management of vascular lesions associated with BD.
In our 10 patients, all endovascular stent grafts were
deployed successfully, with complete exclusion of 11 pseudoa-
neurysms, including the two patients with juxtarenal aneu-
rysms that required placement of fenestrated stent grafts.
Fenestrated graft techniques have been described previ-
ously.19-21 Fenestrated graft procedures are complex and
require experienced interventional skills as well as the ability
to solve intraoperative complications with endovascular
techniques.
We learned from our initial experience that it is critically
important to determine before the procedure the desired
position of the fenestration based on high-resolution CT
imaging to accurately deploy the graft over the ostium of
the target vessel during the operation. Because custom-
made fenestrated stent grafts are currently unavailable in
China, intraprocedural fenestration of the stent graft was
performed by the interventionalists in all procedures.
One of the two patients in our series who presented
with recurrent aneurysms died of aneurysm rupture. Aneu-
rysm recurrence after repair is a major problem and difficult
to avoid completely in BD. As a result, we believe immu-
nosuppressant and anti-inflammatory medication should
be maintained long-term to suppress vasculitis and prevent
recurrent aneurysm after intervention in BD.
According to the 2008 European League Against
Rheumatism (EULAR) recommendations for manage-
ment of BD,22 there is no conclusive evidence to guide the
definite management of major vessel disease in BD. These
recommendations acknowledge that peripheral artery an-
eurysms carry a high risk of rupture and advise surgical
repair accompanied by systemic immunosuppressives. Cy-
clophosphamide and corticosteroids are suggested for the
management of pulmonary and peripheral arterial aneu-
rysms. Retrospective case series and observational studies
advise that recurrences are less common in patients who
receive immunosuppressive therapy.
The proper duration of immunosuppressives after sur-
gery is not addressed in the EULAR recommendations.
Admittedly, our experience in a small series of patients with
BD and aortic involvement does not allow us to conclude
Table II. Meta-analysis of published reports detailing ope
Behçet disease and aneurysmal lesions
First author Year Cases no.
Surgical
no.
Endovascula
no.
Okada14 1997 8 14 . . .
Tüzün15 1997 24 24 . . .
Nitecki11 2004 3 3 . . .
Kalko6 2005 16 19 . . .
Iscan16 2005 20 25 . . .
Kwon5 2008 12 21 . . .
Park17 2001 7 . . . 8
Koo18 2003 9 . . . 11
Nitecki11 2004 2 . . . 2that long-term or even lifetime immunosuppressive therapycan reduce or eliminate recurrent lesions; however, it is
worth noting that the two patients who discontinued im-
munosuppressives experienced complications. Accordingly,
we still advocate long-term immunotherapy as clinically feasi-
ble and the importance of close follow-up of disease activity
with markers, such as ESR and CRP, and vascular imaging.
CONCLUSIONS
Our initial experience suggests that endovascular stent
grafting is a reasonably safe and effective alternative to
surgical repair of aortic pseudoaneurysms in patients with
BD. We recommend aggressive immunosuppression ther-
apy with an aim to normalize the ESR and CRP values
preoperatively. Postoperative corticosteroid therapy and
systemic immunosuppression are also critically important
to prevent recurrent aneurysmal disease, including the for-
mation of pseudoaneurysms at the site of femoral artery
access and in other arteries. Unfortunately, we cannot reach
any conclusion on the preferred duration of corticosteroid
or immunosuppressive therapy. Further studies are neces-
sary to clarify whether endovascular treatment combined
with postoperative immunotherapy can improve the out-
comes of patients with BD and aortic pseudoaneurysm.
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